LSD
{Acid, Tab, Lucy, Lysergic acid diethylamide}
Dose and onset
How? How Much? When? For how Long?
As with any drug, the correct dose for you depends on factors such as weight, gender, metabolism, whether you have taken the drug recently or not, amongst many others.
Read our Me sections on dosing and tolerance for more information.
How you take it matters...
LSD is always taken orally and it is only injected for research purposes. It is commonly dissolved in blotting paper that can be broken down into tabs. other, less common, ways of taking this psychedelic are consuming it in the form of liquid LSD and gelatin
You should place the tab under your tongue for around 10 minutes, after that, you can safely swallow the tab.
If you are going to try LSD for your first time or you are using a new source, we encourage you to take a low dose to avoid a bad trip.
How much?
- Low: 25–100 µg (people report feeling some effects with as little as 20 µg)
- Medium (common): 65–175 µg
- High: 175–250 µg
- Heavy: 250+ µg
When do the effects kick in?
The START time below is when you will usually begin to feel the effects of LSD from the time when you first take it. DURATION is roughly the length of time you will experience the effects, after which the effects will start to wind down and you might start to feel the calm-down/comedown effects.
- Start: 30–90 min
- Peak: 2–3 hours
- Duration: 9–14 hours
This depends heavily on the person and her/his state. Factors such as heart rate and blood pressure or the presence of other drugs in the blood affect the time the drug will take to have an effect. A higher heart rate and blood pressure than normal would make the effects to kick in faster. This can also vary with how much you have taken: the higher the dose you take, the longer the trip will last.
How often can I take it?
Psychedelics are powerful substances and individuals can often find themselves overwhelmed by the new experiences they have gone through. After their first LSD experience, it is not uncommon for individuals to feel like they never need to take LSD or any other psychedelic again. Think carefully to see if this applies to you.
If you are intending on taking it again, for first time users, it is recommended that individuals wait at least three months before dosages in order to properly integrate what they have learned into their everyday life. For more experienced users, the three month resting time is also recommended. You may, however, feel like you can dose sooner than this. Even so, due to the powerful nature of the experience, it is advised you do not take LSD or other psychedelics more frequently than this.
Acid tolerance rapidly builds within the first few hours of consumption. After just two hours, re-dosing will have little to no effect on the experience. This tolerance will last for up to two weeks before it wears off completely. It is therefore advised to avoid re-dosing entirely.
Furthermore, there is a cross tolerance between LSD and Psilocybin (Magic Mushrooms). Taking LSD on Day 1 will mean taking Psilocybin on Day 2 will have little to no effect. The same also applies vice versa. Two weeks must be given for the cross-tolerance to completely fade.
References
1 Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., ... & Nutt, D. J. (2016). The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychological medicine, 46(07), 1379-1390.
2 Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 1268-1278.
3 Murray, R. M., Paparelli, A., Morrison, P. D., Marconi, A., & Di Forti, M. (2013). What can we learn about schizophrenia from studying the human model, drug?induced psychosis?. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 162(7), 661-670.
4 Network, NEPTUNE. Guidance on the clinical management of acute and chronic harms of club drugs and novel psychoactive substances. 2015 http://neptune-clinical-guidance.co. uk/wp-content/uploads/2015/03.NEPTUNE-Guidance-March-2015.pdf)
5 Kaelen, M., Barrett, F. S., Roseman, L., Lorenz, R., Family, N., Bolstridge, M., ... & Carhart-Harris, R. L. (2015). LSD enhances the emotional response to music. Psychopharmacology, 232(19), 3607-3614.
6 Kaelen, M., Roseman, L., Kahan, J., Santos-Ribeiro, A., Orban, C., Lorenz, R., ... & Wall, M. B. (2016).LSD modulates music-induced imagery via changes in parahippocampal connectivity. European Neuropsychopharmacology, 26(7), 1099-1109.
7 Lebedev, A. V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D. J., & Carhart‐Harris, R. L. (2016). LSD‐induced entropic brain activity predicts subsequent personality change. Human brain mapping, 37(9), 3203-3213.
8 Speth, J., Speth, C., Kaelen, M., Schloerscheidt, A. M., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2016). Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. Journal of Psychopharmacology, 30(4), 344-353.
9 Leary, T., Metzner, R., & Dass, R. (1966).The psychedelic experience.Smithsonian Folkways Recordings.
10 Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015). LSD enhances suggestibility in healthy volunteers. Psychopharmacology, 232(4), 785-794.
11 Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., ... & Bullmore, E. (2016).Increased global functional connectivity correlates with LSD-Induced ego dissolution. Current Biology,26(8), 1043-1050.
12 Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., ... & Leech, R. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging.Proceedings of the National Academy of Sciences, 113(17), 4853-4858.
13 Roseman, L., Sereno, M. I., Leech, R., Kaelen, M., Orban, C., McGonigle, J., ... & Carhart‐Harris, R. L. (2016). LSD alters eyes‐closed functional connectivity within the early visual cortex in a retinotopic fashion.Human brain mapping, 37(8), 3031-3040.
14 Terhune, D. B., Luke, D. P., Kaelen, M., Bolstridge, M., Feilding, A., Nutt, D., ... & Ward, J. (2016). A placebo-controlled investigation of synaesthesia-like experiences under LSD. Neuropsychologia.
15 Family, N., Vinson, D., Vigliocco, G., Kaelen, M., Bolstridge, M., Nutt, D. J., & Carhart-Harris, R. L. (2016). Semantic activation in LSD: evidence from picture naming.Language, Cognition and Neuroscience, 1-8.
16 Dolder, P. C., Schmid, Y., Müller, F., Borgwardt, S., & Liechti, M. E. (2016). LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology, 41(11), 2638.
17 Nichols, D. E. (2016). Psychedelics.Pharmacological reviews, 68(2), 264-355.
18 Strassman, R. J. (1984). Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis, 172(10), 577-595.
19 Halberstadt, A. L. (2015).Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural brain research, 277, 99-120.
20 Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 0269881114548296
21 Garcia-Romeu, A., R Griffiths, R., & W Johnson, M. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.Current drug abuse reviews, 7(3), 157-164.
22 Krebs, T. S., & Johansen, P. Ø. (2013). Psychedelics and mental health: a population study. PloS one, 8(8), e63972.
23 Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology, 29(3), 280-288.
24 Johansen, P. Ø., & Krebs, T. S. (2015).Psychedelics not linked to mental health problems or suicidal behavior: A population study. Journal of Psychopharmacology, 0269881114568039.